Ticker Details
Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
IPO Date:	July 24, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.93B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.19 | 2.52%
Avg Daily Range (30 D):	$0.47 | 1.55%
Avg Daily Range (90 D):	$0.50 | 1.75%

Institutional Daily Volume
Avg Daily Volume:	.55M
Avg Daily Volume (30 D):	.72M
Avg Daily Volume (90 D):	.86M

Trade Size
Avg Trade Size (Sh.):	74
Avg Trade Size (Sh.) (30 D):	52
Avg Trade Size (Sh.) (90 D):	59

Institutional Trades
Total Institutional Trades:	6,234
Avg Institutional Trade:	$2.36M
Avg Institutional Trade (30 D):	$3.67M
Avg Institutional Trade (90 D):	$3.05M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.27M
Avg Closing Trade (30 D):	$5.45M
Avg Closing Trade (90 D):	$5M
Avg Closing Volume:	81.14K

News

Apr 6, 2026 @ 11:00 AM Agios to Host First Quarter 2026 Financial Results... Source: Na

Mar 31, 2026 @ 4:08 PM Why Agios Pharmaceuticals Stock Is Up More Than 21... Source: James Brumley

Mar 31, 2026 @ 4:03 PM Insider Sells AGIO Shares Worth $82,000 -- But Con... Source: Andy Gould

Jan 26, 2026 @ 12:00 PM Agios to Host Fourth Quarter and Full Year 2025 Fi... Source: Na

Dec 24, 2025 @ 5:03 PM Here's Why Shares in Agios Pharmaceuticals Popped ... Source: Lee Samaha

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-7.12	$-1.85	$-7.12
Diluted EPS	$-7.12	$-1.85	$-7.12
Revenue	$54.03M	$19.97M	$54.03M
Gross Profit	$47.68M	$18.09M	$47.68M
Net Income / Loss	$-412.78M	$-108.04M	$-412.78M
Operating Income / Loss	$-472.13M	$-121.58M	$-472.13M
Cost of Revenue	$6.35M	$1.88M	$6.35M
Net Cash Flow	$12.88M	$-3.58M	$12.88M
PE Ratio